IRIS
SVICHER, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 39.282
EU - Europa 3.915
AS - Asia 1.575
OC - Oceania 99
SA - Sud America 44
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 13
Totale 44.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 39.253
SG - Singapore 779
IT - Italia 665
DE - Germania 615
UA - Ucraina 490
IE - Irlanda 461
SE - Svezia 411
CN - Cina 404
FR - Francia 355
PL - Polonia 328
KR - Corea 237
GB - Regno Unito 188
FI - Finlandia 138
RU - Federazione Russa 108
AU - Australia 93
BE - Belgio 54
CZ - Repubblica Ceca 45
VN - Vietnam 44
JP - Giappone 32
CA - Canada 24
HK - Hong Kong 20
NL - Olanda 19
IN - India 16
BR - Brasile 14
ES - Italia 13
CL - Cile 11
CO - Colombia 10
EU - Europa 9
CH - Svizzera 8
RO - Romania 7
NZ - Nuova Zelanda 6
TR - Turchia 6
AR - Argentina 5
PK - Pakistan 5
CM - Camerun 4
IQ - Iraq 4
KG - Kirghizistan 4
MX - Messico 4
A2 - ???statistics.table.value.countryCode.A2??? 3
DK - Danimarca 3
EC - Ecuador 3
NG - Nigeria 3
TW - Taiwan 3
UG - Uganda 3
AM - Armenia 2
AT - Austria 2
BD - Bangladesh 2
GH - Ghana 2
IL - Israele 2
KZ - Kazakistan 2
MN - Mongolia 2
MY - Malesia 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
DM - Dominica 1
EG - Egitto 1
GR - Grecia 1
ID - Indonesia 1
IR - Iran 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
SA - Arabia Saudita 1
TN - Tunisia 1
ZW - Zimbabwe 1
Totale 44.945
Salva come PNG Salva come JPEG
Città #
Woodbridge 11.095
Wilmington 10.933
Houston 8.864
Fairfield 1.458
Ann Arbor 924
Chandler 865
Singapore 660
Ashburn 585
Seattle 577
Cambridge 465
Jacksonville 417
Dublin 396
Kraków 324
Medford 286
Dearborn 275
Rome 266
New York 217
Beijing 196
Santa Clara 153
Lawrence 137
San Diego 97
Milan 95
Menlo Park 85
Mülheim 65
Zhengzhou 59
Brussels 53
Moscow 53
Creede 43
Palo Alto 37
Helsinki 35
San Francisco 33
Munich 31
Melbourne 30
Sydney 30
Boardman 29
La Veta 29
Cedarhurst 28
Dong Ket 28
Phoenix 28
Engelhard 26
Redwood City 26
Brno 25
London 25
University Park 25
Falls Church 23
Canberra 22
Council Bluffs 21
Nanjing 20
Olomouc 20
Colorado Springs 18
Hefei 15
Hong Kong 15
Mountain View 15
Verona 15
Guangzhou 14
Norwalk 14
Nuremberg 14
Seoul 12
St. George 12
Toronto 12
Jinan 11
Saint Petersburg 11
San Mateo 11
Shanghai 11
Bari 10
Hanoi 10
Kunming 10
Los Angeles 10
San Jose 10
Nanchang 9
Padova 9
Wuhan 9
Genoa 8
Kilburn 8
Tokyo 8
Amsterdam 7
Nürnberg 7
São Paulo 7
Auburn Hills 6
Auckland 6
Bogotá 6
North Hollywood 6
Prescot 6
Shenyang 6
Albano Laziale 5
Coventry 5
Genzano di Roma 5
Hanover 5
Ho Chi Minh City 5
Indiana 5
Lappeenranta 5
Fuzhou 4
Garbagnate Milanese 4
Hangzhou 4
Hebei 4
Hounslow 4
Islington 4
Mississauga 4
New Bedfont 4
Palermo 4
Totale 40.643
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 505
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 493
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 489
Therapeutic strategies towards HIV-1 infection in macrophages 471
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 455
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 445
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 441
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 440
Novel drug resistance mutations in HIV: Recognition and clinical relevance 437
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 437
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 432
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 431
Understanding HIV compartments and reservoirs 431
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 426
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 425
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 423
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 422
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 418
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 418
HIV-1-associated dementia during HAART therapy 416
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 416
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 413
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 410
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 410
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 408
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 408
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 408
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 407
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 404
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 400
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 399
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 399
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 398
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 397
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 396
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 395
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 394
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 392
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 391
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 391
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 389
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme 389
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 386
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 383
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 383
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 383
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 383
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage 382
Highlights on HIV eradication in 2013 382
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 381
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 380
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 379
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 378
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 377
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 377
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 376
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 376
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 375
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 375
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 374
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 370
Dynamics of NRTI resistance mutations during therapy interruption 369
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 369
The role of HIV infection in neurologic injury 368
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 367
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 366
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 365
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 364
Temporal change in the use of genotypic resistance testing over the years 1999--2003 364
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 363
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 363
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 363
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 360
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 357
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 356
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 356
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype 356
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 354
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 352
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 349
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 348
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 347
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 347
Does residual virus replication during successful HAART lead to HIV-1 genetic evolution? 344
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 343
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 343
Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione] 340
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 337
Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage 336
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 336
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 335
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 335
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 333
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 321
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 320
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 314
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 311
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 307
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 300
Totale 38.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.953 0 0 742 1.064 1.024 1.386 1.130 1.024 1.034 1.002 740 807
2020/20216.998 785 769 761 884 655 768 1.000 663 142 206 250 115
2021/20221.942 116 148 118 103 84 163 90 91 381 149 75 424
2022/20232.393 255 210 147 277 203 471 167 241 189 38 157 38
2023/20241.277 225 35 117 63 128 213 65 25 77 111 26 192
2024/20251.242 175 1.065 2 0 0 0 0 0 0 0 0 0
Totale 45.564